Table 2.

Clinical Outcomes among Treated and Eligible Patients (N = 186)

	TS-High Stratum		TS-Low Stratum
	IROX/Bev	FOLFOX/Bev	FOLFOX/Bev
	(n=61)	(n= 66)	(n=59)
Stopped for PD	45.9%	25.8%	39%
Stopped for Toxicity	13.1%	25.8%	13.6
Death on Study	9.8%	1.5%	0%
CR + PR (90% CI)	33% (23–44)	38% (28–49)	49% (38–61)
CR	0	2 (3.0%)	1 (1.7%)
PR	20 (32.8%)	23 (34.8%)	28 (47.5%)
SD	25 (41.0%)	36 (54.5%)	23 (39.0%)
PD	2 (3.3%)	1 (1.5%)	0
Unevaluable	14 (23.0%)	4 (6.1%)	7 (11.9%)
Subsequent Surgery	5 (8.2%)	7 (10.6%)	15 (25.4%)

TS = thymidylate synthase; IROX = irinotecan and oxaliplatin; Bev = bevacizumab; FOLFOX = folinic acid (leucovorin), 5-Fluorouracil, and oxaliplatin PD = progressive disease; CR = complete response; PR = partial response; SD = stable disease. The TS-Low cohort includes both TS-Low and TS-indeterminate expression